Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.44 |
| ▸ | IGF1R | P08069 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20366860 | 0.81 | KAT6A (0.44) | NPC1RAB9AMEN1KMT2ATRPV1 | |
| SCHEMBL30702144 | 0.81 | KAT6A (0.44) | NPC1RAB9AMEN1KMT2ATRPV1 | |
| SCHEMBL30237854 | 0.81 | KAT6A (0.44) | NPC1RAB9AMEN1KMT2ATRPV1 | |
| SCHEMBL20360251 | 0.79 | HDAC4 (0.51) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL28629835 | 0.79 | IGF1R (0.47) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL22803271 | 0.78 | EPHX1 (0.51) | NPC1RAB9AMEN1KMT2ATRPV1 | |
| SCHEMBL538271 | 0.76 | SMN1; SMN2 (0.51) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL29518583 | 0.76 | SMN1; SMN2 (0.51) | NPC1RAB9AMEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL998884 | 0.75 | SMN1; SMN2 (0.50) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL26613421 | 0.73 | NPC1 (0.55) | NPC1RAB9AMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113292539-B | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-11180471-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-11-23 | — | — | US | disclosed |
| CN-113292539-A | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-108026072-B | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-3319956-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma AG (DE) | 2021-01-06 | — | — | EP | disclosed |
| US-10421742-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-24 | — | — | US | disclosed |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421742-B2 | Substituted oxopyridine derivatives | OGFOD1, VASP, PNPO | NPC1 2232/4885RAB9A 1951/4885MEN1 2632/4885 |
| US-11180471-B2 | Substituted oxopyridine derivatives | OGFOD1, VASP, PNPO | NPC1 2232/4885RAB9A 1951/4885MEN1 2632/4885 |
| US-20180194745-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | NPC1 2232/4885RAB9A 1951/4885MEN1 2632/4885 |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | OGFOD1, VASP, PNPO | NPC1 2232/4885RAB9A 1951/4885MEN1 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.